Trazodone - OWP Pharmaceuticals
Latest Information Update: 28 Aug 2026
At a glance
- Originator OWP Pharmaceuticals
- Class Antidepressants; Erectile dysfunction therapies; Piperazines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action 5-HT2C serotonin receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder in USA (PO, Liquid)
- 12 Jul 2023 Clinical trials in Major depressive disorder in USA (PO) (OWP Pharmaceuticals pipeline, July 2023)
- 13 Jan 2023 Preclinical trials in Major depressive disorder in USA (PO) (OWP Pharmaceuticals pipeline, January 2023)